JP2004517081A - １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物 - Google Patents

１−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物 Download PDF

Info

Publication number
JP2004517081A
JP2004517081A JP2002546529A JP2002546529A JP2004517081A JP 2004517081 A JP2004517081 A JP 2004517081A JP 2002546529 A JP2002546529 A JP 2002546529A JP 2002546529 A JP2002546529 A JP 2002546529A JP 2004517081 A JP2004517081 A JP 2004517081A
Authority
JP
Japan
Prior art keywords
bladder
receptor agonist
urinary incontinence
receptor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002546529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517081A5 (enExample
Inventor
ジョン・メーナート・ショース
デニス・チャールズ・トンプソン
カール・ブルース・ソー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004517081A publication Critical patent/JP2004517081A/ja
Publication of JP2004517081A5 publication Critical patent/JP2004517081A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002546529A 2000-11-29 2001-11-16 １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物 Pending JP2004517081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25020300P 2000-11-29 2000-11-29
PCT/US2001/042949 WO2002044159A2 (en) 2000-11-29 2001-11-16 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence

Publications (2)

Publication Number Publication Date
JP2004517081A true JP2004517081A (ja) 2004-06-10
JP2004517081A5 JP2004517081A5 (enExample) 2005-11-17

Family

ID=22946725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002546529A Pending JP2004517081A (ja) 2000-11-29 2001-11-16 １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物

Country Status (9)

Country Link
US (1) US6864262B2 (enExample)
EP (1) EP1341777B1 (enExample)
JP (1) JP2004517081A (enExample)
AT (1) ATE374192T1 (enExample)
AU (1) AU2002230411A1 (enExample)
CA (1) CA2427098A1 (enExample)
DE (1) DE60130677T2 (enExample)
ES (1) ES2292636T3 (enExample)
WO (1) WO2002044159A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186359B2 (en) * 2010-10-15 2015-11-17 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
PT2838517T (pt) 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
JP7227896B2 (ja) 2016-07-11 2023-02-22 コンテラ ファーマ エー／エス 朝の無動状態を治療するための拍動性薬物送達系

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1300728A (enExample) * 1959-10-20 1962-07-02
BE755015A (fr) * 1969-08-20 1971-02-01 Byk Gulden Lomberg Chem Fab Piperazinyl-alcoylamino-uraciles substitues par un groupe aryle, leurs ethers et thioethers, ainsi que leur procede de preparation
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
NZ209876A (en) * 1983-10-17 1988-03-30 Duphar Int Res Piperazines and pharmaceutical compositions
DK172696B1 (da) * 1987-08-13 1999-05-31 Glaxo Group Ltd Indolderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende forbindelserne
ATE139230T1 (de) 1988-12-15 1996-06-15 Abbott Lab 5-ht-selektive mittel
DE69132691T2 (de) * 1990-06-07 2002-06-20 Astrazeneca Ab, Soedertaelje Indolderivate als 5-HT1-like Agonisten
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
ATE204262T1 (de) * 1991-09-18 2001-09-15 Glaxo Group Ltd Benzanilidderivate als 5-ht1d-antagonisten
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
US5521188A (en) * 1993-09-16 1996-05-28 Bristol-Myers Squibb Company Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
JPH09506101A (ja) * 1993-12-07 1997-06-17 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄ拮抗薬として有用な複素環式ビフェニリルアミド類
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
KR100508626B1 (ko) * 1997-06-27 2005-08-17 니폰 가야꾸 가부시끼가이샤 빈뇨·요실금 치료·예방제 및 트로폰 유도체
JP3441636B2 (ja) 1997-11-21 2003-09-02 株式会社エヌ・ティ・ティ・ドコモ チャネル推定値を求める装置および方法、受信装置ならびに伝送システム

Also Published As

Publication number Publication date
ATE374192T1 (de) 2007-10-15
ES2292636T3 (es) 2008-03-16
WO2002044159A2 (en) 2002-06-06
WO2002044159A3 (en) 2002-08-22
US20040067962A1 (en) 2004-04-08
EP1341777B1 (en) 2007-09-26
WO2002044159A8 (en) 2003-11-20
US6864262B2 (en) 2005-03-08
AU2002230411A1 (en) 2002-06-11
EP1341777A2 (en) 2003-09-10
DE60130677D1 (de) 2007-11-08
CA2427098A1 (en) 2002-06-06
DE60130677T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
CN100406011C (zh) 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
JP4399862B2 (ja) 腸疾患および内臓痛の治療薬
TW200922594A (en) Use of racemic reboxetine for treating or preventing diseases
CN100584323C (zh) 用于治疗下泌尿道病症的α-氨基酰胺衍生物
CN100508980C (zh) 利用δ阿片受体促效药来防止下泌尿系功能障碍的组合物
WO1996011000A1 (en) Methods of treating migraine
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
JP2001512110A (ja) １，４−ジ置換ピペラジン
US6894052B1 (en) Diarylalkylpiperazines active on the lower urinary tract
JP2001511763A (ja) 尿失禁の治療のための５−ｈｔ▲下１ａ▼受容体アンタゴニストの使用
US6864262B2 (en) 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
CN1930123B (zh) 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
JPH1135483A (ja) 頻尿又は尿失禁の治療剤又は予防剤
JP5313686B2 (ja) 失禁治療方法
US20020193383A1 (en) 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
US20070270436A1 (en) Novel amino- and imino-alkylpiperazines
EA007503B1 (ru) N,n-дизамещенные диазоциклоалканы, используемые для лечения заболеваний центральной нервной системы (цнс), вызываемых серотонинергической дисфункцией
US6380185B1 (en) N-substituted benzoyl indoles as estrogenic agents
JPH083045A (ja) 排尿障害改善薬
CN109956919B (zh) 含有丙醇胺结构的苯并呋喃乙酰胺类化合物及其应用
JP6045691B2 (ja) 新規なフッ素化ベンジル酸エステル化合物又はその塩
KR20050044867A (ko) 세로토닌계 장애에 기인한 ｃｎｓ 장애 치료에 유용한ｎ,ｎ-이치환 디아조시클로알칸
JPWO2003097060A1 (ja) トロポロン誘導体を用いた経口投与用頻尿・尿失禁の治療剤又は予防剤若しくは経口投与用睡眠導入剤
HK1201522B (en) Acetic acid ester compound or salt thereof
HK1201522A1 (zh) 乙酸酯化合物或其盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080617